{
    "nct_id": "NCT03448042",
    "official_title": "A Phase Ia/Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Runimotamab Administered Intravenously as a Single Agent and in Combination With Trastuzumab in Patients With Locally Advanced or Metastatic HER2-Expressing Cancers",
    "inclusion_criteria": "Inclusion Criteria\n\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n* Life expectancy of at least 12 weeks\n* Adequate hematologic and end-organ function\n* Acute, clinically significant treatment-related toxicity from prior therapy must have resolved to Grade </=1 prior to study entry\n* Left Ventricular Ejection Fraction (LVEF) >/=50%\n\nHER2-Expressing Breast Cancer-Specific Inclusion Criteria\n\n* Locally tested, Human Epidermal Growth Factor Receptor 2 (HER2)-expressing BC\n* Locally advanced or metastatic BC that has relapsed or is refractory to established therapies\n\nHER2-Expressing Gastric/Gastroesophageal (GEJ) Cancer-Specific Inclusion Criteria\n\n* Adenocarcinoma of the stomach or GEJ with inoperable locally advanced or recurrent and/or metastatic disease, not amenable to curative therapy\n* HER2-expressing tumor (primary tumor or metastasis) as assessed by local lab testing\n* HER2-positive gastric/GEJ cancer must have received prior trastuzumab, cisplatin (or carboplatin or oxaliplatin or investigational platinum agent) and 5-fluorouracil (5-FU)/capecitabine\n\nHER2-Positive Solid Tumor Specific Inclusion Criteria\n\n* HER2-positive tumor (primary tumor or metastasis) as assessed by local (non-central) laboratory testing\n* Locally advanced, recurrent, or metastatic incurable malignancy that has progressed after at least one available standard therapy; or for whom standard therapy has proven to be ineffective or intolerable, or is considered inappropriate; or for whom a clinical trial of an investigational agent is a recognized standard of care; or for whom a clinical trial of an investigational agent is considered an acceptable treatment option\n\nExclusion Criteria\n\n* Pregnant or breastfeeding, or intending to become pregnant during the study or within 140 days after the last dose of runimotamab\n* Significant cardiopulmonary dysfunction\n* Known clinically significant liver disease\n* Positive for acute or chronic Hepatitis B virus (HBV) infection\n* Acute or chronic Hepatitis C virus (HCV) infection\n* Human Immunodeficiency Virus (HIV) seropositivity\n* Poorly controlled Type 2 diabetes mellitus\n* History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias\n* Current treatment with medications that are well known to prolong the Q-wave/T-wave (QT) interval\n* Known clinically significant liver disease\n* Primary central nervous system (CNS) malignancy, untreated CNS metastases, or active CNS metastases (progressing or requiring corticosteroids for symptomatic control)\n* Leptomeningeal disease\n* Spinal cord compression that has not definitively treated with surgery and/or radiation\n* History of autoimmune disease\n* Prior allogeneic stem cell or solid organ transplantation\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}